Skip to content
glp1.howSign in

Access

503A compounding

A section of federal law that lets a licensed pharmacy compound a medication for an individual patient's prescription, outside the FDA approval process.

By the glp1.how editorial teamReviewed

Section 503A of the federal Food, Drug, and Cosmetic Act allows a state-licensed pharmacy or physician to compound a drug for a specific patient based on an individual prescription. These preparations are exempt from the FDA approval process, so the FDA does not review them for safety and effectiveness. They are also exempt from the current good manufacturing practice (CGMP) rules that approved drugs must be made under.

Because oversight is lighter and quality depends heavily on the individual pharmacy, the strength, purity, and sterility of a 503A product can vary. This is a common route for compounded GLP-1 medications, and it is worth discussing the source and its risks with a prescriber before use.

The FDA's overview of compounding law (external link) sets out these 503A exemptions and the patient-specific prescription requirement.

compoundingregulationsafety

Revision history

Updated 2 times since Jul 18, 2026 · show changes
  1. v3

    Body revised

  2. v2

    Body revised

  3. v1

    Change tracking began

Related guides

  • How compounded GLP-1 medications are made — and how that differs from the branded pens · A compounded GLP-1 is mixed from raw active ingredient at a pharmacy; it does not come off a branded production line. This guide explains how the drug substance is sourced, how the formula and dose are set, how a sterile compounding pharmacy makes the vial, and how that compares with the tightly controlled, FDA-approved process behind Ozempic, Wegovy, and Zepbound.
  • "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you · "Research peptides" are GLP-1 drugs such as semaglutide, tirzepatide, and retatrutide, sold as powder in vials stamped "research use only, not for human consumption." That label is a legal workaround and says nothing about safety. This guide covers where these products come from, what independent testing found inside the vials, why the "research" disclaimer does not make them regulated or safe, and the documented harms behind a rise in poison-control calls.
  • How to verify a pharmacy is legitimate: BeSafeRx, NABP, and your state board · Our sourcing guides keep ending on the same instruction (verify the pharmacy with your state board, the NABP, or FDA's BeSafeRx) without saying how. This is the step-by-step: the free tools each one offers, what red flags to look for, how to pull a pharmacy's license record, and how to check your own pen's lot number against FDA's counterfeit alerts. About five minutes, start to finish.
  • Pharmacy sources for GLP-1 medications: compounded, telehealth, and counterfeit risks · The brand shortages that made compounded GLP-1s widely available ended in late 2024 and early 2025, and where people get these drugs has shifted since. Counterfeit Ozempic has turned up in the legitimate supply chain three times. This guide shows how to tell the fully legitimate routes from compounded grey areas and outright dangerous sellers, and how to vet any source before you inject.
  • Talking to a pharmacist about compounded medications and sourcing · If you're considering or already using a compounded GLP-1, your pharmacist can help you check whether a source is legitimate and safe. Here are six questions to ask and what a good answer sounds like.
  • Applying for a GLP-1 patient assistance program: step by step · Novo Nordisk's PAP and Lilly Cares can provide Ozempic or Trulicity free to people who qualify by income and insurance status, but as of September 2026 neither covers Wegovy, Zepbound, Saxenda, or Foundayo. Here's who qualifies, the 2026 income limits in dollars, the documents you need, your prescriber's role, turnaround and renewal, what to do if you're denied, and how PAPs differ from savings cards and direct-pay.

Related terms

  • GMP (Good Manufacturing Practice) · A regulatory standard ensuring medications are consistently produced and controlled to quality standards — a key marker of legitimacy for compounded or manufactured drugs.
  • Effectiveness · How well a medication performs in everyday, real-world use, as opposed to the controlled conditions of a clinical trial.
  • GLP-1 · A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.

Was this helpful?

Improve this page